Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.52 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4220810 | 0.89 | CYP4F2 (0.62) | CYP4F2CYP4A11PKMUSP2SMN1; SMN2 | |
| SCHEMBL29346988 | 0.86 | CYP4F2 (0.54) | CYP4F2CYP4A11PKMUSP2SMN1; SMN2 | |
| SCHEMBL29346987 | 0.86 | CYP4F2 (0.54) | CYP4F2CYP4A11PKMUSP2SMN1; SMN2 | |
| SCHEMBL23246952 | 0.86 | CYP4F2 (0.47) | CYP4F2CYP4A11PKMUSP2SMN1; SMN2 | |
| SCHEMBL15353442 | 0.86 | CYP4F2 (0.49) | CYP4F2CYP4A11PKMUSP2SMN1; SMN2 | |
| SCHEMBL15353124 | 0.86 | CYP4F2 (0.49) | CYP4F2CYP4A11PKMUSP2SMN1; SMN2 | |
| SCHEMBL1119882 | 0.85 | PKM (0.45) | CYP4F2CYP4A11PKMUSP2SMN1; SMN2 | |
| SCHEMBL31171520 | 0.85 | CYP4F2 (0.53) | CYP4F2CYP4A11PKMUSP2SMN1; SMN2 | |
| SCHEMBL31171637 | 0.85 | CYP4F2 (0.53) | CYP4F2CYP4A11PKMUSP2SMN1; SMN2 | |
| SCHEMBL2799709 | 0.84 | PKM (0.47) | CYP4F2CYP4A11PKMUSP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546404-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546404-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME (US) | 2013-10-01 | — | — | US | disclosed |
| EP-1966151-B1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORP (US) | 2011-10-05 | — | — | EP | disclosed |
| EP-1966151-B1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORP (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| EP-1966151-A1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| WO-2007070398-A1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPK10 | CYP4F2 1666/4885CYP4A11 1639/4885PKM 2652/4885 |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | CYP4F2 2249/4885CYP4A11 2627/4885PKM 2981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.